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INTRODUCTION: 
 
The incidence of Type 2 Diabetes Mellitus is turning out to be a near 
epidemic in India, and so is its complications like Diabetic retinopathy. Many of 
these patients belong to productive socioeconomic age group. Therefore 
identifying the risk factors for Diabetic Macular Edema and keeping them under 
check is of paramount importance in saving the vision of Diabetics, reducing 
morbidity and thus reducing the economic burden due to blindness in our 
country. 
Diabetic retinopathy (DR) is a leading cause of visual disability and 
blindness among Diabetics. It is a major microvascular complication of diabetes 
and is frequently accompanied by lipid exudation. Dyslipidemia leads to the 
development of hard exudates and Clinically Significant Macular Edema 
(CSME) which interferes with vision. The elevated lipid levels are associated 
with endothelial dysfunction plays an important role in the pathogenesis of 
Diabetic Retinopathy, especially in the breakdown of blood-retinal barrier. It’s 
important to find an association between serum lipid profile with diabetic 
retinopathy and its severity. 
It is estimated that diabetes mellitus affects 4 percent of the world’s 
population, nearly half of whom have some degree of diabetic retinopathy at a 
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given time. Diabetic retinopathy is a very common, long-term, microvascular 
complication of Diabetes Mellitus and a leading cause of visual disability and 
preventable blindness. It is considered the hallmark of generalized 
microangiopathy occurring in a Diabetic. In India the prevalence of diabetic 
retinopathy in general population is 3.5%, and the prevalence of diabetic 
retinopathy in the population with diabetes  was  18.0%.  In  a population-  
based study in South India, diabetic retinopathy was detected in 1.78% of the 
diabetic patients who were screened. 
 
 
While risk factors for the development and progression of diabetic 
retinopathy are multifactorial, the duration of the disease and the age of the 
patient are said to be the strongest predictors. Other risk factors like 
hypertension, pregnancy, blood glucose level control and presence of 
nephropathy are shown to have a strong association. Dyslipidemia, 
microalbuminuria, Body Mass Index and smoking are some of the factors 
whose role as predictors of diabetic retinopathy is not well established. 
 
 
 
Diabetic retinopathy is frequently accompanied by lipid exudation. 
Elevated serum lipid levels are associated with increased risk of retinal hard 
exudate in patients with diabetic retinopathy. Although retinal hard exudate 
usually goes in hand with diabetic macular edema, increasing amounts of 
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exudate appear to be independently associated with an increased risk of visual 
impairment. The elevated lipid levels are also associated with endothelial 
dysfunction, which appears to play an important role in the pathogenesis of 
diabetic retinopathy, particularly in relation to  the  breakdown  of blood-  
retinal barrier. 
 
The association between serum lipid levels and diabetic retinopathy 
has been investigated in few studies. Some studies show a positive relationship 
between serum cholesterol and low-density lipoprotein levels and retinal hard 
exudation. Other studies show serum triglyceride levels as being important in 
the progression of retinopathy. Certain other studies show no relationship 
between serum lipid levels and diabetic retinopathy. 
 
 
The current study was undertaken to determine the association of 
serum lipid profile with diabetic retinopathy and its severity. The conflicting 
reports in the literature regarding the association between serum lipid levels and 
diabetic retinopathy and the paucity of studies relative to the existing case load, 
has warranted this study. 
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ANATOMY OF RETINA: 
 
The retina is the innermost coat of the eye. It extends from the optic disc to the 
oraserrata. It can broadly be divided into two distinct regions: 
Posterior pole and Peripheral retina separated by the retinal equator. The 
Retinal equator is an imaginary line lying in line with the exit of the four vortex 
veins. The Posterior pole refers to the area of the retina posterior to the retinal 
equator. It includes two distinct areas: the optic disc and the macula lutea. 
Posterior pole of the retina is best examined by the slit-lamp Indirect 
Biomicroscopy using a +78D or +90D lens and direct ophthalmoscopy. 
The Optic disc: It is a pink coloured, well-defined circular area of 1.5 
mm diameter. At the optic disc all the retinal layers terminate except the nerve 
fibres, which pass through the lamina cribrosa to run into the optic nerve(second 
cranial nerve). A depression seen in the optic disc is called the physiological 
cup. The central retinal artery and the central retinal vein emerge through the 
centre of this cup. 
The Macula: The macula lutea is also called the yellow spot. It is 
relatively deeper red than the surrounding retina and is situated at the posterior 
pole temporal to the optic disc. It is about 5.5 mm in diameter. The 
Foveacentralis is a central depressed part in the macula. It is about 1.5 mm in 
diameter and is the most sensitive part of retina. In its centre is a shining pit 
called foveola(0.35 mm diameter) which is situated about 2 disc diameters (3 
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mm) away from the temporal margin of the optic disc and about 1 mm below 
the horizontal meridian. An area of 0.8 mm size (which includes foveola and 
some surrounding area) does not contain any retinal capillaries and is called the 
FOVEAL AVASCULAR ZONE (FAZ). Surrounding the fovea are the 
parafoveal and perifoveal areas. 
 
 
Peripheral retina refers to the area bounded posteriorly by the retinal equator 
and anteriorly by the oraserrata. Peripheral retina is best examined with indirect 
ophthalmoscopy or Goldman three mirror contact lens. 
 
 
 
 
The retina contains at least 10 distinct layers. They are from outer to inner: 
 
 
 (1) the retinalpigment epithelium  
 
 
(2) the layer of rods and cones (photoreceptor layer)  
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(3) the external limiting membrane 
 
 
(4) the outer nuclear layer 
 
 
 (5) the outer plexiform layer 
 
 
 (6) the inner nuclear layer 
 
(contains the bipolar, amacrine and horizontal cells and nuclei of the fibres of   Muller) 
 
 
(7) the inner plexiform layer 
 
 
 (8) the ganglion cell layer 
 
 
 (9) the nerve fibre layer  
 
 
(10) the internal limiting membrane 
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BLOOD SUPPLY OF THE RETINA: 
 
The inner 6 layers of retina are supplied by the central retinal artery and the 
outer 4 layers are supplied by the choroidal artery. 
The Arterial System: 
 
The central retinal artery is a branch of the Ophthalmic artery which is inturn 
the first branch of the Internal carotid artery. The central retinal artery is an end 
artery. It enters the optic nerve approximately 1 cm behind the globe. 
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The artery wall has 3 anatomical layers: 
 
- Intima: innermost layer which is composed of a single layer of endothelium 
 
resting on a collagenous zone. 
 
- Internal elastic lamina: separates the intima from the media. 
 
- Media: consists mainly of smooth muscle. 
 
- Adventitia: is the outermost layer and is composed of loose connective tissue. 
 
The Retinal arterioles arise from the central retinal artery. Their wall contains 
smooth muscle, but unlike the arteries, the internal elastic lamina is 
discontinuous. 
Retinal capillaries supply the inner two-thirds of the retina (inner 6 layers of 
retina), while the outer one-third(outer 4 layers of retina) are supplied by the 
choriocapillaris. The inner capillary network is located in the ganglion cell 
layer, and an outer capillary plexus lies in the inner nuclear layer. Capillary-free 
zones are present around arterioles and at the fovea (foveal avascular zone – 
FAZ). 
The Retinal capillaries do not have smooth muscle and elastic tissue; and their 
walls consist of the following. 
• The Endothelial cells: whichform a single layer on the basement membrane 
and are linked by tight junctions forming the inner blood–retinal barrier. 
• The basement membrane: which lies beneath the endothelial cells with an 
outer basal lamina enclosing the pericytes. 
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• The Pericytes: which lie external to endothelial cells.They are supporting 
cells. They have many pseudopodial processes which envelop the capillaries. 
Pericytes have contractile properties and are thought to participate in the 
autoregulation of the microvascular circulation. 
 
 
 
 
 
 
 
 
The Venous system: 
 
Retinal venules and veins drain blood from the capillaries and finally drain into 
the Central Retinal vein. 
• Small venules are larger than capillaries but have a similar structure. 
 
• Larger venules contain smooth muscle and merge to form veins. 
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• Veins contain a small amount of smooth muscle and elastic tissue in their 
walls and are relatively distensible. Their diameter gradually enlarges as they 
pass posteriorly towards the central retinal vein. 
 
 
 
 
 
 
 
 
DIABETIC RETINOPATHY: 
 
Among the 422 million Diabetics in the world, India is among the top 
three countries with high diabetic population. 
India has become the second biggest nation harbouring 64.5million 
diabetics next to China(102.9million diabetics). 
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Prevalence of Diabetic Retinopathy: 
 
23 – 34% of patients of diabetes mellitus will have diabetic retinopathy 
 
It is more common in type 1 diabetes than in type 2 diabetes and sight 
threatening disease is present in up to 10% diabetics. Proliferative diabetic 
retinopathy (PDR) affects about 10% of the diabetic population; type1 diabetics 
are at increased risk, with an incidence of up to 90%after 30 years. 
Type 1 Diabetics are more prone to develop PDR leading to visual deterioration 
while the main cause of visual impairment is Type 2 Diabetics is Diabetic 
Macular edema. 
 
 
DIABETES MELLITUS IN EYE: 
 
Ophthalmic complications of diabetes mellitus include: 
 
• Common complications: 
 
○ Diabetic Retinopathy. 
 
○ Diabetic Iridopathy (minor iris transillumination defects). 
 
○ Refractive error. 
 
• Uncommon complications 
 
○ Recurrent hordeolum. 
 
○ Xanthelasmata. 
 
○ Accelerated senile cataract. 
 
○ Neovascular glaucoma (NVG). 
 
○ Ocular motor nerve palsy. 
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○ Reduced corneal sensitivity. 
 
• Rare complications: 
 
Diabetic Papillopathy, pupillary light-near dissociation, Wolfram syndrome 
(consists of progressive optic atrophy and multiple neurological and systemic 
abnormalities), acute-onset of senile cataract, rhino-orbital 
mucormycosis(fungal infection). 
 
 
Risk factors 
 
• Duration of diabetes is the most important risk factor. In patients diagnosed 
with diabetes before the age of 30 years, the incidence of Diabetic retinopathy 
after 10 years is 50%, and after 30 years 90%. DR seldom develops within 5 
years of the onset of diabetes or before puberty, but about 5% of type  2 
diabetics have DR at the time of presentation. Duration of diabetes is a stronger 
predictor for proliferative disease than for Diabetic maculopathy. 
• Poor control of diabetes. It is proven that tight blood glucose control, when 
instituted early, can prevent or delay the development or progression of DR. 
Type 1 diabetics appear to obtain greater benefit from good control than type 2. 
Raised HbA1c level is associated with an increased risk of PDR. 
• Pregnancy is said to be associated with rapid progression of DR. Predisposing 
factors include greater pre-pregnancy severity of retinopathy, poor pre- 
pregnancy control of diabetes(overt diabetes), control exerted too rapidly during 
the early stages of pregnancy and pre-eclampsia. The risk of progression is 
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directly related to the severity of DR in the first trimester. If substantial DR is 
present, frequency of review should reflect individual risk. Diabetic macular 
edema usually resolves spontaneously after pregnancy and need not be treated if 
it develops in later pregnancy. 
• Hypertension, which is very common in patients with type 2 diabetes, should 
be rigorously controlled (<140/80 mmHg). Tight control can to be particularly 
beneficial in type 2 diabetics with maculopathy. Cardiovascular disease and 
previous stroke are also predictive factors. 
• Nephropathy, if severe, is associated with worsening of DR. Hence, the 
treatment of renal disease (e.g. renal transplantation) may be associated with an 
improvement of retinopathy and a better response to photocoagulation. 
• Other risk factors include hyperlipidaemia, smoking, previous cataract 
surgery, obesity and anemia. 
Pathogenesis of Diabetic Retinopathy: 
 
DR is predominantly a microangiopathy where small blood vessels are 
particularly susceptible to damage from high glucose levels. Direct 
hyperglycaemic effects on retinal cells also to play a role in causing DR. Many 
angiogenic stimulators and inhibitors have been found out; vascular endothelial 
growth factor (VEGF) seem to be of paramount importance in the former 
category. 
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Pathophysiology of DR: 
 
 
Specific retinal capillary changes comprises the selective loss of pericytes and 
basement membrane thickening, which favor capillary occlusion and lead to 
retinal non perfusion, decompensation of the endothelial barrier function, which 
leads to serum leakage and retinal edema occurs. 
A variety of hematologic and biochemical abnormalities have been correlated 
with the prevalence and severity of Diabetic retinopathy: 
 increased platelet adhesiveness 
 
 increased erythrocyte aggregation 
 
 dyslipidemia 
 
 defective fibrinolysis and increased fibrinogen 
 
 abnormal growth hormone levels 
 
 upregulation of vascular endothelial growth factor (VEGF) 
 
 abnormalities in blood viscosity 
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Potential visual loss in diabetics with diabetic retinopathy may be due to the 
following: 
 Diabetic macular edema (due to capillary leakage) 
 
 macular ischemia (due to capillary occlusion) 
 
 sequelae from ischemia-induced neovascularisation 
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Pathological changes in DR: 
 
 
1. Terminal arteriole : 
 
Shows sclerotic changes, hyaline thickening (hyaline arteriosclerosis), 
corkscrew coiling, narrowed lumen and occlusion. 
Venous side- ‘U’ shaped capillary loops, varicose dilatation. 
 
2. Basement membrane – Thickened due to deposition of glycoproteins and 
layers are separated by debris and lipid droplets. 
3. Pericytes loss - This leads to disruption of blood retinal barrier. ( as pericyte 
maintains transport function and contractility) 
Endothelial cell death may occur. 
 
GHOST CAPILLARIES - occluded functionless vessels , basement 
membrane present but pericytes and endothelial cells are absent. 
• Adjacent to ghost capillaries – distended tortuous shunt vessel develops 
to maintain the circulation. 
4. Microaneurysm – Saccular or ampulliform shaped thin walled outpouchings 
and arise from side of capillaries near areas of capillary closure. In late stages – 
thickened and laminated due to PAS positive material deposition and they 
thrombose and lumen is occluded by laminated hyaline. 
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5 .Hemorrhage – most common in Outer plexiformlayer. Large hemorrhages 
may extend into the subhyaloid space 
6. Exudates: in OPL – retina and Henle s layer – macula 
7.Cotton wool spots – Infarct in NFL 
8. NEW VESSEL : derived from venous side. 
 
• Closely packed tufts , looping is clearly seen. After rupturing through 
ILM grows as pannus like network between retina and vitreous. 
• They are fragile. Those which have attached to posterior face of retracting 
vitreous are liable to rupture and bleed. 
• The mesenchyme from which the proliferating vessels are derived is a 
source of fibroblasts so that the vessels become enveloped in connective 
tissue which when contracts lead to Retinal Detachment. 
9. Degeneration of retinal nervous tissue: 
 
• Both cells and dendrites of neurons – swollen and fragmented 
 
• In late stages there is severe decrease in ganglion cells and NFL and 
gliosis of inner layers. 
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10. DIABETIC IRIDOPATHY : 
 
• Vacuolation of pigment epithelium of iris due to accumulation of 
glycogen in epithelial cells .Retinal neovascularisation may be 
accompanied by growth of new vessels in iris leading to peripheral 
anterior adhesions and secondary angle closure glaucoma. 
 
 
 
 
DIABETIC RETINOPATHY TYPES: NPDR AND PDR 
 
 
 
1. Mild NPDR 
 
 At least 1 microaneurysm or intraretinal hemorrhage.
 
 Hard/soft exudates may or may not be present.
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2. Moderate NPDR 
 
 Moderate microaneurysms or intraretinal hemorrhage.
 
 Early mild Intra retinal microvascular abnormalities (IRMA)
 
 Hard exudates or soft exudates may or may not present
 
3. Severe NPDR. Any one of the following (4-2-1 Rule): 
 
 Four quadrants of severe microaneurysms or intraretinal hemorrhages.
 
 Two quadrants of venous beading.
 
 One quadrant of IRMA.
 
4. Very severe NPDR. Any two or more of the of the following (4-2-1 Rule) 
 
 Four quadrants of severe microaneurysms or intraretinal hemorrhages.
 
 Two quadrants of venous beading.
 
 One quadrant of IRMA.
 
 
Retinal microvascular changes that occur in NPDR are limited to the retina and 
never extends beyond the internal limiting membrane (ILM). Characteristic 
findings in NPDR are microaneurysms, cotton-wool spots or soft exudates 
(boundary sentinels of infarction), areas of capillary nonperfusion, intraretinal 
microvascular abnormalities (IRMAs), “dot-and-blot” intraretinal hemorrhages, 
retinal edema, hard exudates, arteriolar abnormalities, and dilation and beading 
of retinal veins. NPDR can affect visual function through 2 mechanisms: 
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increased intraretinal vascular permeability, resulting in macular edema, and 
variable degrees of intraretinal capillary closure, resulting in macular ischemia. 
 
 
PDR: 
 
1. PDR without High Risk Characteristics (Early PDR). 
 
2. PDR with High Risk Characteristics (Advanced PDR). 
 
High risk characteristics (HRC) of PDR are the following: 
 
 Neovascularisation Disc (NVD) 1/4 to 1/3 of disc area with or without 
vitreous haemorrhage (VH) or preretinal haemorrhage (PRH) 
 NVD < 1/4 disc area with VH or PRH 
 
 Neovascularisation Elsewhere (NVE)> 1/2 disc area with VH or PRH 
 
 
 
CRITERIA FOR HIGH RISK PDR: 
 
Any 1 of following: 
 
 Mild Neovascularisation Disc (NVD) with vitreous haemorrhage 
 
 Moderate to severe NVD with or without vitreous haemorrhage ( ¼ to 1/3 
disc area of NVD) 
 Moderate (1/2 disc area ) Neovascularisation Elsewhere (NVE) with 
vitreous haemorrhage 
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Any 3 of the 4 retinopathy risk factors 
 
 Presence of vitreous or preretinal hemorrhages 
 
 Presence of new vessels 
 
 Location of new vessels on or near the optic disc 
 
 Moderate to severe extent of the new vessels 
 
Advanced diabetic eye disease (ADED): 
 
It is the ultimate end result of uncontrolled proliferative diabetic 
retinopathy. It leads to severe loss of vision. It is marked by the following 
complications; 
 Persistent vitreous haemorrhage 
 
 Tractional retinal detachment 
 
 Neovascular glaucoma. 
 
 
Vision loss in patients with diabetic retinopathy are associated with the 
following abnormalities: 
 capillary leakage ( Diabetic macular edema) 
 
 capillary occlusion (macular ischemia, diabetic papillopathy) 
 
 sequelae from ischemia-induced neovascularization (vitreous 
hemorrhage, tractional retinal detachment, and neovascular glaucoma) 
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HARD EXUDATES 
 
Hard exudates are morphological signs of blood retinal barrier breakdown. 
Biochemically, there are composted of lipoproteins of plasma origin. They are 
deposited in the inner and outer plexiform layers and are exuded from 
microaneurysms. Areas of hard exudates are surrounded by an accumulation of 
macrophages. When arranged in dense conglomerates, they may cause localized 
scotoma. 
 
 
 
 
 
 
 
 
 
 Caused due to the break down lipid products of neuronal elements. 
 
 Colour: They are discrete yellow material 
 
 Location: Outer plexiform layer of the retina 
 
 Appearance: Circinate arrangement seen around leaking MA/capillaries 
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 Hard exudates indicate Abnormal vascular leakage 
 
 They are removed by the phagocytic action of macrophages by 6 months 
to 12 months 
 
 
. 
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CLINICALLY  SIGNIFICANT  MACULAR  EDEMA : 
 
 
 
 
Clinically significant macular edema (CSME) is detected on clinical 
examination by ophthamoscopy, as defined in the ETDRS. 
 
 
The Early Treatment Diabetic Retinopathy Study (ETDRS) was the first 
prospective, randomized clinical trial of photocoagulation in diabetic patients 
with less than high-risk PDR to establish standard treatment paradigms for 
managing DME. 
 
 
CSME includes Any one of the following: 
 
• Retinal thickening within 500 μm of the centre of the macula 
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• Exudates within 500 μm of the centre of the macula, if associated with retinal 
thickening; the thickening itself may be outside the 500 μm 
 
 
 
 
 
 
 
• Retinal thickening one disc area (1500 μm) or larger, any part of which is 
within one disc diameter of the centre of the macula and demonstrates CMO if 
present. 
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Studies now use the term center-involving macular edema or similar 
terminology, based on whether or not the fovea appears thickened on OCT 
scans. Most algorithms for pharmacologic intervention use this simplified, 
OCT-based definition. 
 
 
Early Treatment Diabetic Retinopathy Study (ETDRS): 
 
The study aimed at the following Questions: 
 
1. Is photocoagulation effective for treating Diabetic macular edema (DME)? 
 
2. Is photocoagulation effective for treating diabetic retinopathy? 
 
3. Is aspirin effective for preventing progression of diabetic retinopathy? 
 
Eligibility: Mild nonproliferative diabetic retinopathy through  early 
proliferative diabetic retinopathy, with visual acuity 20/200 (6/60) or better in 
each eye. 
Randomization: 3711 participants: 1 eye randomly assigned to photocoagulation 
(scatter and/or focal) and 1 eye assigned to no photocoagulation; patients 
randomly assigned to 650 mg/day aspirin or placebo. 
Outcome variables: Visual acuity less than 5/200 for at least 4 months; visual 
acuity worsening by doubling of initial visual angle (eg, 20/40 to 20/80); 
retinopathy progression. 
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Macular edema results: 
 
1. Focal photocoagulation for DME decreased risk of moderate vision loss 
(doubling of initial visual angle). 
2. Focal photocoagulation for DME increased chance of moderate vision gain 
(halving of initial visual angle). 
3. Focal photocoagulation for DME reduced retinal thickening. 
 
Early scatter photocoagulation results: 
 
1. Early scatter photocoagulation resulted in a small reduction in the risk of 
severe vision loss (<5/200 for at least 4 months). 
2. Early scatter photocoagulation is not indicated for eyes with mild to 
moderate diabetic retinopathy. 
3. Early scatter photocoagulation may be most effective in patients with type 2 
diabetes mellitus. 
Aspirin use results: 
 
1. Aspirin use did not alter progression of diabetic retinopathy. 
 
2. Aspirin use did not increase risk of vitreous hemorrhage. 
 
3. Aspirin use did not affect visual acuity. 
 
4. Aspirin use reduced risk of cardiovascular morbidity and mortality. 
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DIABETIC MACULAR EDEMA: 
 
 
 
 
Diabetic Maculopathy: Diabetes can affect macula in several ways, macular 
edema being the most frequent. It is also the most frequent cause of visual loss 
in the background stage. 
Diabetic Macular Edema is defined as a collection of interstitial fluid within 
the macula with or without lipid exudates and with or without cystoid changes. 
Clinically, macular edema is retinal thickening within two disc diameters of the 
center of the macular (not fluorescein leakage without thickening). Retinal 
thickening or hard exudates with adjacent retinal thickening that threatens or 
involves the center of the macular is considered to be clinically significant 
macular edema (CSME) 
Macular edema may be Focal, Diffuse, Ischemic or a mixed variety. 
 
It results mainly from breakdown of the inner blood retinal barrier. It may be 
present during any stage of retinopathy, though, the percentage of patients with 
macular oedema increases with increasing severity of retinopathy. Other factors 
influencing the development of macular edema are the age at onset of diabetes, 
type and the duration of diabetes. According to the Wisconsin Epidemiologic 
Study of Diabetic Retinopathy, “the prevalence rate of macular edema is 10% in 
the diabetic in the older onset patients and even in this group it is seen earlier 
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after the discovery of diabetes in the older onset patients and even in this group 
it is higher in those that are being treated with insulin (5% may already have 
macular edema at the time of diagnosis)” 
Diabetic maculopathy (foveal edema, exudates or ischaemia) is the 
most common cause of visual impairment in diabetic patients, particularly 
in type 2 diabetics.. The fluid is initially located between the outer 
plexiform and inner nuclear layers; later it can eventually involve the 
inner plexiform and nerve fibre layers, until eventually the entire 
thickness of the retina becomes oedematous. The central accumulation of 
fluid the fovea forms a cystoid pattern named the cystoid macular edema 
(CME) that is readily detectable on optical coherence tomography (OCT) 
and assumes a central flower petal pattern on Fundus Fluorescein 
Angiography (FFA) 
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Types of Diabtic Macular Edema: 
 
 Focal maculopathy: A well-circumscribed retinal  thickening 
along with complete or incomplete rings of exudates FFA shows 
late, focal hyperfluorescence due to leakage from a microaneurysm 
and dilated capillary segments, usually with good macular 
perfusion.This is a localized leak from a microaneurysm giving rise 
to a hard exudate, deposited at the junction of normal and abnormal 
retina. Laser photocoagulation is often very successful in 
preventing or retarding visual loss and may even result in the visual 
improvement. However if the exudates are too far advanced, their 
resorption does occur following the laser treatment but retinal 
function may already have been destroyed due to which visual 
improvement may become impossible. Macular plaque is a long 
standing continued damage due to leakage into the macula. 
 
 
• Diffuse maculopathy: There is diffuse retinal thickening, along with 
associated with cystoid changes; caused due to extensive capillary leak; 
there are typically scattered microaneurysms and small intraretinal 
haemorrhages . Landmarks may be obscured by edema, which may render 
localization of the fovea impossible. FFA shows mid- and late- 
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phase diffuse hyperfluorescence, It is characterized by a wide spread 
leakage of fluid from retinal capillaries, IRMAs &microaneurysms, 
leading to a diffuse macular oedema and a reduction in vision. Clinically, 
there is retinal thickening, loss of macular reflex and at a later stage 
development of cystoid macular edema due to a breakdown of the 
intervening normal retinal tissue. It may also present as scattered  
exudates in a non – circinate pattern. Without laser treatment in such 
cases, there is a continued fluid accumulation and destruction of the 
foveal architecture. Laser photocoagulation aims at limiting this 
destruction of macular structure and function. 
 
 
Focal macular edema may be associated with hard exudates, which are 
precipitates of plasma lipoproteins. Because resorption of extravascular aqueous 
occurs at a faster rate than that of plasma lipids, lipid residues often remain 
behind after the fluid has resorbed. These yellow-to-white lipid deposits 
accumulate within the outer and inner plexiform layers or beneath the sensory 
retina. 
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Focal and diffuse macular edema. 
 
 
 
A, Color fundus photograph showing circinate hard exudates surrounding a 
group of microaneurysms in an example of focal macular edema. 
B, Fluorescein angiogram confirming the microaneurysms, which appear as a 
group of punctate foci of hyperfluorescence in FFA. 
C, Color fundus photograph shows diffuse macular edema demonstrating 
diffuse thickening of the retina with glistening surface. 
D, Fundus Fluorescein angiogram confirming the diffuse intraretinal leakage. 
 
Diffuse macular edema is characterized by extensive retinal capillary leakage 
and widespread breakdown of the blood–retina barrier, often accumulating in a 
cystoid configuration in the perifoveal macula (cystoid macular edema) 
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Whether the pattern of macular edema is focal or diffuse, treatment decisions 
are based upon lesions meeting defined size and location criteria that determine 
clinical significance. 
 
 
 
 
 Ischaemic maculopathy: 
 
This type of maculopathy occurs as a result of non-perfusion of the parafoveal 
capillaries with or without intraretinal fluid accumulation. It usually coexists 
with the other types, but in its pure form is the least easy to recognize and 
diagnose. Ophthalmoscopically one may find a dull appearance to the macula. 
However an FFA is necessary to confirm the diagnosis. It is essentially 
untreatable. Improvement of a poor diabetic control may retard the progression, 
but too rapid an implementation can also lead to a transient worsening of retinal 
ischemia. Prepoliferative and proliferative changes should be actively looked  
for in such cases and treated early because it will help reduce the risk of further 
visual loss from extra – macular complications. Microaneurysms may cluster at 
the margins of zones of capillary nonperfusion of retinal arterioles and can 
result in larger areas of nonperfusion and progressive ischemia. Evidence of 
enlargement of the foveal avascular zone greater than 1000microns in diameter 
generally leads to visual loss. 
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Signs are variable and the macula may look relatively normal in 
Ophtalmoscopy, despite reduced visual acuity. In other cases PDR may be 
present. 
FFA shows capillary non-perfusion(CNP) at the fovea (an enlarged FAZ) along 
with other areas of capillary non-perfusion at the posterior pole and the 
periphery. 
 
 
ISCHEMIC MACULOPATHY: 
 
 
 
 
 Mixed: Diabetic maculopathies rarely exist isolated and most commonly 
have two or more of the components listed above. Management is the 
treatment of remediable elements after assessing their respective 
contributions by FFA. 
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Other mechanisms in which macula is affected in diabetes are as follows: 
 
 Traction on the macula by a fibrous tissue proliferation causing a drag 
of the retinal tissue, surface wrinkling or detachment of the macula. 
 Intraretinal or preretinal (subhyaloid) haemorrhage on the macula. 
 
 Lamellar or full – thickness macular hole formation. 
 
 Any combination of the preceding. 
 
 
 
FUNDUS FLUORESCEIN ANGIOGRAPHY: 
 
FFA is a serial study of the vascular pattern of the retina and the choroid at 
specific time intervals to establish, confirm the diagnosis, to aid treatment 
decision and assess response to treatment. 
Usually Retinal capillaries are absent in two regions: 
 
1. Foveal Avascular Zone (300-400micron). 
 
2. A 1.5 mm strip adjoining oraserrata. 
 
 The Inner blood retinal barrier: (walls of retinal vessels)
 
- Zonulae occludens. 
 
- 1:1 endothelial andpericyte cell ratio. 
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 Outer blood retinal barrier:
 
- retinal pigment epithelial tight junction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Technique: Fluorescein Angiography requires the use of a fundus camera 
equipped with excitation and barrier filters. The Fluorescein dye(C20 H10 O5 
Na2) is injected intravenously, usually through an antecubital vein with 
sufficient speed to produce high contrast images of the early phases of the 
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angiogram. 85% fluorescein is bound to serum proteins and 15% free unbound 
form in plasma. 
 
 
 
 
 
 
FUNDUS CAMERA 
 
White light from a flash is passed through a blue excitation filter. Blue 
light (wavelength 465-490 nm) is then absorbed by the unbound fluorescein 
molecules, and the molecules fluoresce [emitting light with a longer wavelength 
in the yellow-green spectrum (520-530nm) ]. A barrier filter blocks any 
reflected light so that the images capture only light emitted from the fluorescein. 
Images are acquired immediately after injection and continue for ten minutes 
depending on the pathology being imaged. The images are recorded digitally. 
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Preparations of sodium fluorescein available: 
 
 
 10 % Solution of 5 ml, 5% soln of 10ml(500mg).
 
 25% Solution of 3 ml(750mg)
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The Normal Fluorescein Angiography 
 
 
 
Once Sodium Fluorescein dye is injected into the antecubital vein, the dye 
passes through the Ophthalmic artery and finally reaches the short posterior 
ciliary arteries and appears in the retina and choroid usually within 8-12 
seconds. This is called the arm-retina time. This dependent on the age and 
cardiovascular status of the patient and the speed of dye injection. 
 
The filling of the choroidal circulation is seen as the choroidal flush which in 
FFA appears as a patchy and mottled hyperfluorescence as the choroidal lobules 
fill. The dye appears in the retinal circulation1-3 seconds after it appears in the 
choroidal circulation (11-18 seconds after injection). This is followed by the 
early arteriovenous phase (AV phase)which describes the filling of the retinal 
arteries, arterioles and capillaries. Then comes the late arteriovenous phase or 
laminar venous phase as the Sodium fluorescein dye fills the veins in a laminar 
pattern. 
 
In the normal macula, the capillary-free zone is seen as dark black area named 
the FAZ (Foveal Avascular Zone) due to blockage of choroidal fluorescence by 
Xanthophyll pigment and tightly packed retinal pigment epithelial cells in the 
macula. The peak phase with maximal fluorescence after dye injection occurs at 
about 30 seconds and then the recirculation phases follow. After 10 minutes 
 
fluorescein dye is not seen in retinal vessels at all however but structures like 
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the optic nerve head, Bruch’s membrane, and sclera are stained with fluorescein 
and continue to fluoresce leading to delayed fluorescence. 
 
Abnormal Fluorescein Angiography 
 
 
 
Any Deviation from normal FFA is described as relative fluorescence. 
Hypofluorescence refers to a reduction from the normal expected fluorescence 
and hyperfluorescence refers to an increased fluorescence. 
 
Hypofluorescence may occur due to a blocking effect or due to any vascular 
filling defect. Blockage of normal fluorescence can be due to any opacity 
anterior to the fluorescence hiding its view, like corneal scar, cataract, vitreous 
hemorrhage, and nerve fibre layer hemorrhage etc. Choroidal fluorescence may 
be blocked by retinal hemorrhage, subretinal precipitates, or even an abnormal 
collection of normal material in the retinal pigment epithelium as occurs with 
lipofuscins seen in Stargardt’s disease. Vascular filling defect can cause an 
absence or delay in fluorescein dye entry in the tissue affected. Causes of 
vascular filling defects include retinal or choroidal vascular occlusion or with 
occlusion of the short posterior ciliary arteries supplying the optic nerve. 
 
Hyperfluorescence can be due to fluorescein leakage, staining, pooling or by 
transmission defects and autofluorescence. Leaking fluorescein may come from 
incompetent blood vessels which leaks such as with 
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Choroidal neovascularization or diabetic neovascularization or though a 
diseased retinal pigment epithelium that no longer blocks leakage of fluorescein 
from the choroid. Areas of leakage in an FFA show gradual enlargement and 
blurring of their margins. This is different from staining of structures that stain. 
Staining results in increasing fluorescence throughout the angiogram but the 
margins remain well defined and distinct. Normal structures like the optic disc  
and sclera will stain. but pathological structures like drusen and disciform scars, 
also stain with sodium fluorescein. Pooling is caused when  fluorescein 
gradually fills a fluid-filled space. A transmission, or window defect, is formed 
when a layer that normally blocks fluorescence is missing. This usually occurs 
when the retinal pigment epithelium is missing and the bright choroidal 
fluorescence is seen early in the FFA. The intensity of the fluorescence fades 
and the margins remains welldefined. Ocular structures such as optic nerve head 
drusen and lipofuscin normally fluoresce even before fluorescein dye injection 
and this is called Autofluorescence. Some authorities suggest that specifically 
equipped scanning laser ophthalmoscopes and fundus cameras can use the 
fluorescence of lipofuscin to document the health of the RPE layer instead of 
using sodium fluorescein dye. 
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Phases in FFA: 
 
 
i. Prearterial phase 
 
ii. Arterial phase 
 
iii. Arterio venous phase 
 
iv. Venous phase 
 
v. Transit phase 
 
vi. Recirculation phase 
 
 
 
 
PREARTERIAL PHASE: The larger choroidal vessels and choriocapillaries 
 
begins to fill. Fluorescein is faint patchy irregularly scattered. 
 
ARTERIAL PHASE: Dye fills the most choroidal vessels and also retinal 
vessels. Flourescein increases in intensity. Fast & turbulent circulation, 
hence no lamination. 
 
 
 
ARTERO-VENOUS PHASE: Complete filling of arteries and capillaries. 
 
 
First evidence of laminar flow in vein. 
 
 Blood stream is faster in the centre of the lumen so unbound dye is 
appears to stick on the side creating laminar pattern. 
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VENOUS PHASE: Arteries begins to emptying and veins are completely filled. 
 
At the junction of two veins, the inner lamina of each vein merge and create 
third lamina. As dye filling increases, lamina enlarge and completely fills the 
vein. 
 
 
 
TRANSIT PHASE: Includes the arterial, arterio-venous, venous phase. It 
 
represents the complete passage of fluorescein containing blood through the 
retina and choroid. FAZ is better identified. 
 
 
 
RECIRCULATION PHASE: Fluorescein at low concentration continues to pass 
 
through fundus circulations. Vessels slowly empty the fluorescein and become 
gray. Staining of disc-normal. 
45 
 
FFA IN DIABETIC MACULAR ISCHEMIA: 
 
 
 
 
 
 
 
 
Role of Fundus Fluorescein Angiography (FFA) in Diabetic Retinopathy: 
 
Background Diabetic Retinopathy 
 
 Baseline 
 
 Maculopathy – unexplained visual loss 
Clinically Significant Macular Edema 
 Ischemia 
 
 Extent 
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 Location 
 
Preproliferative Diabetic Retinopathy 
 
 Extent of retinal ischemia : Capillary non perfusion areas 
 
 Detect NVE, NVD which are not clinically evident 
 
 IRMAs 
 
 Maculopathy 
 
Proliferative Diabetic Retinopathy 
 
 Confirm clinical findings 
 
 Residual or recurrent proliferations after laser treatment 
Background Diabetic Retinopathy 
Regular clinical checkup is mandatory to look for the development of the 
following: 
 Maculopathy 
 
 Preproliferative changes 
 
 New vessels on the disc elsewhere  
 
 CSME 
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Focal laser treatment for CSME consists of direct laser treatment, grid 
laser treatment, or a combination of the two. Based on previously mentioned 
randomized clinical trials for treatment of diabetic macular edema, following 
guidelines are recommended. 
 Eyes with macular edema that is not clinically significant should 
generally be watched without treatment. 
 Eyes with CSME with center involvement should be considered for 
immediate laser treatment. 
 Eyes with CSME without center involvement should also be considered 
for immediate laser treatment, if the visual acuity is good. 
In general, the following lesions are considered treatable: 
 
 Focal leaks of more than 500 microns from center of macula causing 
thickening of exudation. 
 Focal leaks 300 – 500 microns from center of macula, if the treatment is 
not likely to destroy the remaining perifoveal capillary network. 
 Ares of diffuse leakage not treated previously 
 
 Avascular zones other than the normal foveal avascular zone, not 
previously treated. 
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Factors favoring treatment include the evidence of advancing edema and 
that the treatable lesions causing the edema are located more than 500 
microns form the center of fovea. 
 
 
 
Technique: Usually a FFA is done prior to deciding the treatable lesions. In the 
ETDRS protocol these treatable lesions were as follows: 
1. Discrete points of retinal hyperfluorescence or focal leakage, which were 
500 micron or more from the centre of the macula causing hard exudates 
and / or retinal thickening. 
2. Focal leaks 300 – 500 microns from the centre of the macula thought to 
be causing retinal thickening and / or hard exudates. 
3. Areas if diffuse leakage within the retina (IRMA or diffusely leaking 
capillary bed). 
4. Thickened retinal avascular zones (except for normal FAZ). 
 
 
 
 
The treatment techniques could be 
 
(a) Focal Photocoagulation or 
 
(b) Grid treatment 
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Focal Photocoagulation : spot size from 50 to 200 microns of 0.1 seconds 
duration can be used to directly treat all the focal fluorescein leaks, which could 
include the microaneurysms, IRMAs or short capillary segments. The goal of 
treatment is too obtain closure or obliteration of the leak. The end point is a 
whitening or darkening of the microaneurysms. 
 
 
 
Grid Photocoagulation: This is applied to areas of thickened retina showing 
diffuse fluorescein leakage on FFA or capillary drop out. Burns of light 
intensity are placed in this area using 50 to 200 microns spots of 0.1 sec or 0.5 
sec duration. Grid is not placed within 500 micron of center of the macula or 
within 500 micron of the disc margin as they may lead to central scotoma, but 
can be placed in the papillomacular bundle. Peripherally, it can be placed in all 
directions upto 2 disc diameter from the center of the macula, or to the border of 
the PRP treatment. The main aim of the grid treatment is to ‘tickle’ the retinal 
pigment epithelial cells and stimulate the retino-choroidal pump to hasten the 
absorption of fluid and not to the destroy the region. 
Follow-up treatment: At 4 weeks after treatment the patients are 
reviewed. If some obvious treatable lesions are missed at the initial session, they 
are treated four months after the initial treatment confirming this with FFA. 
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Follow up should be done at 4 monthly intervals. The patients should be 
explained in details that laser treatment that this is done to prevent any further 
visual loss and cannot revert the already lost vision. 
 
 
 
DYSLIPIDAEMIA IN DIABETICS: 
 
 
Hyperglycemia can result in cell damage by the following pathways: 
 
• polyol pathway, 
 
• upregulation of hexosamine pathway, 
 
• advanced glycation end product (AGE) with increased expression of 
AGE receptors 
• activation of protein kinase C (PKC) isoforms. 
 
 
 
However, the corelation between traditional lipid markers and Diabetic 
Retinopathy remains unclear. Of all the hyperglycemia associated pathways,  
the protein kinase C (PKC) and Advanced Glycation Endproduct(AGE) 
pathways interact with blood Lipids. Protein kinase C (PKC) is a family of 10 
enzymes, in which the 1/2 isoform appears to be closely associated with the 
development of Diabetic Retinopathy. Hyperglycemia results in an increase in 
glucose flux through the glycolysis pathway, that increases the de novo 
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synthesis of Diacylglycerol (DAG), the main activator of PKC in physiology. 
Moreover, the accumulated long-chain Fatty Acids are immediately converted 
into DAG. The expression of the PKC 1/2 isoform is increased in patients with 
diabetes mellitus. As PKC is involved in numerous physiological pathways, its 
upregulation contributes to the pathogenesis of Diabetic Retinopathy in the  
form of differential synthesis of extracellular matrix (ECM) proteins and their 
remodeling, increased release of angiogenic factors, endothelial and leukocyte 
dysfunction resulting in capillary occlusion and leukostasis, and eventually 
changes in the blood flow to retina. 
Advanced Glycation Endproducts(AGEs) are generated by nonenzymatic 
reaction between reducing sugars and lipoproteins. Advanced Glycation End 
products are formed at a slow and constant rate in the normal body starting at 
embryonic development and accumulated over time. However, the formation of 
AGE is markedly increased in diabetes due to the increased availability of 
glucose. In a highly oxidative environment like retina, the accumulation of lipid 
and modification of proteins will lead to an accumulation of lipoxidation end 
products (ALEs). 
 
 
 
There are two kinds of AGEs related to the pathogenesis of DR: 
 
Carboxy-ethyl-pyrrole and malon-di-aldehyde (MDA). Advanced 
GlycationEndproducts(AGE)s are important pathogenic mediators which can 
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lead to a lot complications in Diabetes. They are seen in the retinal vessels of 
diabetics, and their levels correlates with those in serum and with the severity  
of the Diabetic retinopathy. The interaction of AGEs with specific cell surface 
receptors has been postulated in the onset of Diabetic Retinopathy. The AGE 
receptors include RAGE, galectin-3, CD36, and macrophage scavenger 
receptor. It is believed that exposure to high levels of Advanced Glycation End 
products(AGE)s leads to renal and vascular complications. In a study done by 
Hammes et al., the retinal capillaries showed an increased expression of AGEs 
and loss of pericytes 26 weeks after the development of diabetes in rats. 
Treatment with an AGE inhibitor, aminoguanidine (pimagedine) hydrochloride, 
significantly reduced AGE accumulation and prevented the rapid development 
of microaneurysms, pericyte loss and acellular capillaries. 
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REVIEW OF LITERATURE: 
 
 
 
1. Association of serum lipids with diabetic retinopathy in urban South 
Indians— the Chennai Urban Rural Epidemiology Study (CURES) 
Eye Study—2 
M. Rema, B. K. Srivastava, B. Anitha, R. Deepa and V. Mohan 
 
Aim 
 
To study the association of serum lipids with diabetic retinopathy (DR) in Type 
2 diabetic subjects. 
Methods 
 
Type 2 diabetic subjects (n = 1736) were randomly selected from the Chennai 
Urban Rural Epidemiology Study (CURES), which was carried out on a 
representative population of Chennai in South India. DR was diagnosed by 
retinal colour photography and classified according to the Early Treatment 
Diabetic Retinopathy Study (ETDRS) grading system. Classification of lipid 
abnormalities was done according to the National Cholesterol Education 
Programme–Adult Treatment Panel III (NCEP–ATP III) Guidelines. 
Results 
 
The mean serum cholesterol ( P = 0.024), serum triglycerides ( P = 0.017) 
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and non-high-density lipoprotein (HDL)-cholesterol ( P =0.025) concentrations 
were higher in subjects with DR compared with those without DR. Multiple 
logistic regression analysis revealed that after adjusting for age, gender,  
duration of diabetes, total cholesterol Standardised regression estimate (SRE) = 
1.178,  95%  confidence  interval  (CI)  1.042,  1.331,P  =  0.014),  non-HDL- 
cholesterol  (SRE  =   1.169,   95%  CI  1.040,   1.313,   P  =   0.012)  and serum 
 
triglycerides (SRE = 1.292, 95% CI 1.136, 1.467, P = 0.001) were associated 
 
with DR and non-HDL-cholesterol (SRE = 1.264, 95% CI 1.000, 1.592, P = 
 
0.045) and lowdensity 
 
lipoprotein (LDL)-cholesterol (SRE = 1.453, 95% CI 1.107, 1.896, P = 0.005) 
with diabetic macular oedema (DME). After adjusting for HbA 1c and 
body mass index, only triglycerides maintained a significant association with 
DR (SRE = 1.137, 95% CI 1.000, 1.291, P = 0.007) and LDL-cholesterol with 
macular oedema (SRE = 1.358, 95% CI 1.034, 1.774, P = 0.026). 
 
Conclusions 
 
There is a significant association of serum triglycerides with DR and LDL- 
cholesterol with DME. 
Diabet. Med. 23, 1029–1036 (2006) 
 
 
 
2. Study of glycated haemoglobin, lipid profile and uric acid levels in 
diabeticretinopathy 
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P. Usha Kiran1, B. Srinivas2 
 
1Assistant professor, G.S.L.Medical College, Rajahmundry-533294, A.P, 
India.2Deputy civil surgeon, Rangaraya Medical College, Kakinada-533003, 
A.P, India. 
 
 
Abstract: Diabetic patients with and without complications show a difference 
in serum uric acid pattern in relation to duration of disease along with glycemic 
status, lipid derangements and complications associated with the disease. 
HbA1c studies were taken to know the blood sugar levels for the past 3 months 
to assess the glycemic control. Study of lipid profile is also taken to assess the 
micro vascular complications like Retinopathy in diabetic cases. Behaviour of 
uric acid levels may indicate the ongoingpatho physiology in diabetes  in 
relation to glycemic control, onset and progression of complications such as 
retinopathy. The present study consists of 75 cases of chronic diabetes with 
retinopathy as a complication in the age of 45-75 years. The values are 
compared with the values of 50 apparently healthy non-diabetics which will fall 
on the same age group. All the subjects were from ophthalmology department  
of Govt. General Hospital, Kakinada and also from Nayana Eye Care Hospital, 
Kakinada. 
Results: The Mean, SD Values of HbA1C were high in whole blood group of 
diabetic retinopathy cases, 8.903, +1.549 as compared to control group. The 
Mean, SD values of uric acid of diabetic retinopathy cases are 4.796, +0.944, 
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which doesn‟t show much difference with control group, It shows that poor 
glycemic control plays a major role on the onset and progression of diabetic 
retinopathy. In diabetic retinopathy statistically significant lipid profile changes 
observed. Serum uric acid level has not shown statistically significant changes 
in diabetic retinopathy. It shows that uric acid values have no significance. 
 
 
3. Relationship of Serum HbA1c and Fasting Serum Lipids with 
Central Macular Thickness in Patients with Type 2 Diabetes Mellitus 
 
 
Abstract 
 
Background: Diabetic retinopathy, the most common retinal vascular 
disease, is the leading cause of new-blindness in adults during the third 
through sixth decades of life. 
Purpose: To determine the correlation between central macular thickness 
(CMT) and both HbA1c and fasting serum lipids level in early stage non 
proliferative diabetic retinopathy. 
Results: The patients were divided into two groups as HbA1c >8.67% 
(Group I, n: 60) and HbA1c ≤8.67% (Group II, n: 72). The mean CMT of 
better eyes was 273.28±34.61 μm. The mean CMT of worse eye was 
304.40±64.31 μm. According to comparison between Group I (HbA1c 
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>8.67%) and Group II (HbA1c ≤8.67%) the mean CMT’s were not different 
in two groups (P: 0.37). 
Main findings: HbA1c level (8.76%) were significantly higher than normal 
upper limits in patient even under diabetic medication. In further analyses 
the mean CMT’s was not different in worse eye in Group I and Group II and 
it was not significantly different in better eyes in these two group either. 
Conclusion: Even we did not observed any correlation between level of 
HbA1c and the degree of CMT statistically in either worse or better eye, 
result of our study showed that patient had increased macular thickness even 
early stage of NPDR while having significantly higher HbA1c even under 
systemic medication. 
Brief Summary: The purpose of the current study was to determine the 
correlation between diabetic macular edema and both HbA1c and fasting 
serum lipids in early stage non proliferative diabetic retinopathy. We did not 
observed any correlation between level of HbA1c and the degree of central 
macular thickness (CMT) statistically in either worse or better eye. Our 
results may indirectly evidence of insufficient metabolic treatment can cause 
macular edema prior to other retinal signs. 
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4. Oxidized Low-Density Lipoprotein and the Incidence of Proliferative 
Diabetic Retinopathy and Clinically Significant Macular Edema 
Determined From Fundus Photographs 
 
 
Ronald Klein, MD, MPH; Chelsea E. Myers, MStat; Kristine E. Lee, MS; 
Andrew D. Paterson, MBChB; 
Karen J. Cruickshanks, PhD; Michael Y. Tsai, PhD; Ronald E. Gangnon, PhD; 
Barbara E. K. Klein, MD, MPH 
IMPORTANCE Studies have shown oxidized low-density lipoprotein to be 
associated with the incidence of proliferative retinopathy and other 
complications of type 1 diabetes mellitus. Because low-risk interventions are 
available to modify oxidized low-density lipoprotein, it is important to examine 
the relationships between this factor and the incidence of proliferative 
retinopathy and of macular edema, 2 important causes of visual impairment in 
people with type 1 diabetes. 
OBJECTIVE: To determine the association of oxidized low-density lipoprotein 
with the worsening of diabetic retinopathy and the incidence of proliferative 
retinopathy and of macular edema. 
DESIGN, SETTING, AND PARTICIPANTS Of 996 participants with type 1 
diabetes in the Wisconsin Epidemiologic Study of Diabetic Retinopathy, 730 
were examined up to 4 times 
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(1990-1992, 1994-1996, 2005-2007, and 2012-2014) over 24 years and had 
 
assays of oxidized low-density lipoprotein and fundus photographs gradable 
for diabetic retinopathy and macular edema. Analyses started July 2014 and 
ended February 2015. 
MAIN OUTCOMES AND MEASURES Worsening of diabetic retinopathy, 
incidence of proliferative diabetic retinopathy, and incidence of macular edema 
as assessed via grading of color stereo film fundus photographs. The levels of 
oxidized low-density lipoprotein collected from serum samples at the time of 
each examination were measured in 2013 and 2014 from frozen serum. 
RESULTS The cohort at baseline had a mean (SD) level of oxidized low- 
density lipoprotein of30.0 (8.5) U/L. While adjusting for duration of diabetes, 
glycated hemoglobin A1c level, and other factors, we found that neither the 
level of oxidized low-density lipoprotein at the beginning of a period nor the 
change in it over a certain period was associated with the incidence of 
proliferative diabetic retinopathy (hazard ratio [HR], 1.11 [95%CI, 0.91-1.35],P 
= .30; odds ratio [OR], 1.77 [95%CI, 0.99-3.17], P = .06), the 
incidence of macular edema(HR, 1.04 [95%CI, 0.83-1.29], P = .74; OR, 1.08 
[95%CI, 0.44-2.61], P = .87), or theworsening of diabetic retinopathy (HR, 0.94 
[95%CI, 0.83-1.07], P = .34; OR, 1.32 [95%CI,0.83-2.09], P = .24). 
CONCLUSIONS AND RELEVANCE Our findings do not provide evidence  
for a relationship between increasing levels of serum oxidized low-density 
lipoprotein and the incidence of macular edema or the worsening of diabetic 
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retinopathy in persons with type 1 diabetes. The potential increase in the HR for 
incident proliferative retinopathy, with an increase in oxidized low-density 
lipoprotein level over the preceding period, warrants further investigation of this 
relationship. 
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PART TWO 
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AIMS AND OBJECTIVES: 
 
 
 
 To study the relationship between fundus fluorescein angiographic 
patterns of diabetic maculopathy and serum lipid levels. 
 
 
 To evaluate  the  relationship between serum lipid levels and retinal 
hard exudates in patients with diabetic retinopathy. 
 
 
 
STUDY PERIOD: 6months (April-October 2017) 
 
SAMPLE SIZE: 50 patients. 
 
ETHICAL CLEARANCE: Ethical Committee approval letter obtained 
 
FINANCIAL SUPPORT: Nil 
 
 
 
METHODOLOGY: 
 
 
A total of 50 patients with diabetic retinopathy attending the O.P.D of the 
Department of Ophthalmology of Government Rajaji Hospital Madurai for 
ophthalmic evaluation detected to have diabetic maculopathy, who satisfy the 
inclusion criteria will be included in this study. 
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INCLUSION CRITERIA: 
 
 
 
 
All patients of age > 21 years, with a confirmed diagnosis of Diabetic 
Maculopathy diagnosed with slit lamp biomicroscopy with 90D lens, or 
clinically and/or angiographically confirmed Diabetic Macular Edema. 
(Diabetes mellitus diagnosed on the basis of the diabetes diagnostic criteria of 
the World Health Organization, and the patients were under medical treatment 
by an experienced Diabetologist) 
 
 
EXCLUSION CRITERIA: 
 
1. Eyes with active proliferative retinopathy with vitreous haemorrhage and 
dense media opacities 
2. Macular Edema due to causes other than Diabetis. 
 
3. Very old uncompliant and Immunocompromised patients. 
 
4. Patients who underwent Panretinal photocoagulation or anti-VEGF 
treatment 
5. Gestational Diabetis. 
 
6. Those with hypersensitivity to fluorescein dye or any other medications. 
 
7. Patients with renal insufficiency, cardiovascular diseases. 
 
8. Patients on hypolipidemic drugs and known case of Hyperlipidaemia 
Syndrome. 
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Subjects shall be evaluated for entry into the study and seen that they fulfill all 
eligibility criteria, and none of the exclusion criteria, will be invited to 
participate in the study. Written informed consent obtained from all of them. 
METHOD OF COLLECTION OF DATA: 
 
Patients with Diabetic Maculopathy attending OPD of the department of 
Ophthalmology of GovtRajaji Hospital, Madurai. 
Informed consent will be taken. 
 
A detailed history including demographics, ocular disease, past medical illness, 
drug history and personal history will be taken. 
Ophthalmological examination will include: 
 
Best corrected visual acuity assessed using illuminated Snellens chart. 
Near vision assessed with Times New Roman chart. 
Colour vision will be tested (monocularly) with Ishihara test plates. 
 
Slit lamp examination for anterior segment especially lenticular opacities 
Applanation tonometry 
Refraction by retinoscopy 
 
Amslers grid assessment for macular involvement. 
 
Fundus examination with direct, indirect ophthalmoscope and slit lamp 
biomicroscopy 90 D lens for grading of diabetic retinopathy and macular 
assessment. 
Fundus photograph will be taken before fundus flourescein angioigraphy. 
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Investigations like complete hemogram, urine examination, Biochemical tests- 
FBS, PPBS, HBA1C, lipid profile, serum creatinine will be recorded and ECG 
will be done. Medical fitness for performing the procedure will be taken. Patient 
will be explained about the procedure and proper written consent will be taken. 
Pupil will be dilated using tropicamide and phenylephrine for 20 to 30 min 
before the procedure. Emergency medicines will be kept available if needed and 
the test is performed in the presence of an Anaesthetist. 
 
 
Fundus flourescein angiography will be done as follows: 
 
Patient will be explained about the procedure. Patient will be seated and 
flourescein injected intravenously (after a test dose) followed by fundus 
photographs taken serially through dilated pupil for each eye separately. From 
the good quality fundus photographs, presence of leakage of perifoveal area will 
be recorded for both early and late frames separately. The presence of macular 
edema will be evaluated by comparing early-phase and late (5minute) phase 
frames for the presence of late phase leakage in the perifoveal area. Any 
enlargement of perifoveal avascular zone in late frames will be evaluated for 
ischemic maculopathy. These findings will be recorded separately. All poor 
quality FFA photographs will be excluded. . Following the procedure patient 
will be informed regarding urine and skin discolouration. 
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RESULTS AND INTERPRETATION 
 
 
 
STATISTICAL METHOD: 
 
The information collected regarding all the cases were recorded in a Master 
Chart. 
Data analysis was done with the help of computer using Statistical 
Package for Social Sciences (SPSS) software developed by IBM corporation. 
 
 
Using this software- range, frequencies, percentages, and‘p’ values were 
calculated. 
“Chi Square” test was used to find the association btw lipid profile and 
FFA findings 
A 'p' value of less than 0.05 is taken to denote significant relation 
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OBSERVATIONAL ANALYSIS 
 
 
 
Table 1: AGE DISTRIBUTION 
 
Age distribution of the group varied from 30-80 years. They were 
categorised into 5 classes with a class interval of 10years each. Majority of 
Diabetics developed Diabetic Maculopathy between the range of 50-60 years of 
age. 
 
 
 
 
 
 
 
AGE DISTRIBUTION: 
35% 
 
30% 
 
25% 
 
20% 
 
15% 30% 
32% 
30% Age 
10% 
 
5% 
4% 4% 
0% 
30-40 yrs 40-50 yrs 50-60 yrs 60-70 yrs 70-80 yrs 
68 
 
 
 
Table 2 : SEX DISTRIBUTION 
 
Among the 50 patiets with Diabetic Maculopathy, 21 were females and 
29 were males. There was a male preponderance in the group. 
 
 
 
 
 
 
 
 
 
 
 
 
SEX DISTRIBUTION 
42% 
58% males: 58% 
females: 42% 
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Table 3 : PERCENTAGE DISTRIBUTION IN EYES: 
 
It was found that among the 50 Diabetic patients, 22 patients had Right 
Eye affected with Maculopathy, 24 patients had Left eye affected with 
Maculopathy and 4 patients had both eyes affected with Maculopathy. Majority 
of the patients had Left Eye affected by Diabetic Maculopathy. 
 
 
 
 
 
 
 
 
PERCENTAGE DISTRIBUTION IN EYES 
48% 
50% 44% 
45% 
40% 
35% 
30% 
25% 
PERCENT 
20% 
15% 
8% 
10% 
5% 
0% 
RIGHT EYE (44%) LEFT EYE (48%) BOTH EYES (8%) 
70 
 
Table 4 :DISTRIBUTION OF OCCUPATION: 
 
Among the 50 patients, occupation plot showed that more were coolies 
and housewives. 
 
OCCUPATION NUMBER (out of 50 patients) 
COOLIE 16 (32%) 
OFFICER 12 (24%) 
DRIVER 3 (6%) 
HOUSEWIFE 15 (30%) 
OTHERS(PAINTER,TAILOR) 4 (8%) 
 
 
8% 
32% 
30% 
COOLIE 
OFFICER 
DRIVER 
HOUSEWIFE 
OTHERS 
6% 
24% 
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Table 5 :DISTRIBUTION ON BMI: 
 
Acoording to Body Mass Index(BMI) as per South East Asian population 
standards, the patients in the study were grouped into 3 classes: Normal, 
overweight and. obese. It was found out that most of the patients had a normal 
BMI. 
 
BODY MASS INDEX (BMI) PERCENTAGE 
18.5-22.5 (Normal) 25 (50%) 
22.5-25 (overweight) 17 (34%) 
>25 (obese) 8 (16%) 
 
 
 
 
 
 
 
BMI Distribution 
100% 
90% 
80% 
70% 
60% 
50% 
40% 
30% 
20% 
10% 
0% 
50% 
BMI Distribution 
34% 
16% 
Normal (18.5-22.5) Over weight (22.5-25) Obese (>25) 
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Table 6 : COMPARISON OF LIPID PROFILE: 
 
Among the 50 Diabetic patients, fasting lipid profile showed that 19 had 
no abnormality,18 had higher cholesterol levels,9 had high Triglycerides and 4 
had high LDL in blood. 
 
Lipid Profile n (%) 
Cholesterol 18 (36.0) 
LDL 4 (8.0) 
Triglycerides 9 (18.0) 
Normal 19 (38.0) 
Total 50 (100.0) 
 
 
 
LIPID PROFILE: 
40% 
35% 
30% 
25% 
20% 
38% 36% 
15% LIPID PROFILE: 
10% 18% 
5% 8% 
0% 
normal lipid 
38% 
CHOLESTEROL TRIGLYCERIDES LDL 8% 
36% 18% 
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Table 7 :COMPARISON OF TOTAL FFA FINDINGS: 
 
 
 
 
Among the 50 DiabeticMaculopathy patients, the Fundus fluorescein 
Angiography showed 2 main patterns: 
1. Ischemic maculopathy(increased FAZ size and capillary nonperfusion 
areas) 
2. Blocked fluorescence (CSME due to hard exudates and areas of leakage 
from microaneurysms) 
It was seen that the patients with Blocked fluorescence outnumbered 
those with Ischemic maculopathy 
 
 
 
 
TOTAL FFA findings 
80% 
 
70% 
 
60%  72%  
50% 
 
40% 
FFA findings 
30% 
 
20% 
 28%  
10% 
 
0% 
Blocked fluorescence Ischemic maculopathy 
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Table 8 :FFA FINDINGS IN PATIENTS WITH HIGH CHOLESTEROL: 
 
Among the 50 patients, 18 had high cholesterol levels in Lipid profile. On FFA, 
17 showed Blocked fluorescence and 1 showed Ischemic Maculopathy. Patients 
with high cholesterol had developed more blocked fluorescence in FFA (p value 
0.042) statistically significant 
 
 
 
Lipid Profile 
FFA 
Blocked 
Fluorescence 
due to HE 
n (%) 
Ischemic 
Maculopathy(↑FAZ) 
n (%) 
Cholesterol 17 (58.6) 1 (12.5) 
Normal 12 (41.4) 7 (87.5) 
Total 29 (100.0) 8 (100.0) 
p value 0.042– Significant 
 
 
 
87.50% 
90% 
 
80% 
 
70% 
59% 
60% 
 
50% 41% 
Cholesterol 
Normal 
40% 
 
30% 
 
20% 13.00% 
10% 
 
0% 
Blocked Fluorescence Ischemic maculopathy 
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Table 9 :FFA FINDINGS IN PATIENTS WITH HIGH 
TRIGLYCERIDES: 
Among the 50 patients, 9 had increased levels of Triglycerides in Lipid profile. 
On FFA, 5 showed Blocked fluorescence and 4 showed Ischemic Maculopathy. 
 
 
 
Lipid Profile 
FFA 
Blocked 
Fluorescence 
due to HE 
n (%) 
Ischemic 
Maculopathy(↑FAZ) 
n (%) 
Triglycerides 5 (29.4) 4 (36.4) 
Normal 12 (70.6) 7 (63.6) 
Total 17 (100.0) 11 (100.0) 
p value 1.000– Not Significant 
 
 
 
80% 
71% 
70% 63.60% 
60% 
 
50% 
36.40% 
40% 
29% 
Triglycerides 
Normal 
30% 
 
20% 
 
10% 
 
0% 
Blocked Fluorescence Ischemic maculopathy 
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Table 10 :FFA FINDINGS IN PATIENTS WITH HIGH LDL: 
 
Among the 50 patients, 4 had high LDL levels in Lipid profile. On FFA, 2 
showed Blocked fluorescence and 2 showed Ischemic Maculopathy. 
 
 
 
 
 
 
 
Lipid Profile 
FFA 
Blocked 
Fluorescence due 
to HE 
n (%) 
Ischemic 
Maculopathy(↑FAZ) 
n (%) 
LDL 2 (14.3) 2 (22.2) 
Normal 12 (85.7) 7 (77.8) 
Total 14 (100.0) 9 (100.0) 
p value 1.000– Not Significant 
 
 
 
86% 
90% 
77.80% 
80% 
70% 
60% 
50% 
40% 
LDL 
Normal 
30% 22.20% 
20% 
14% 
10% 
0% 
Blocked Fluorescence Ischemic maculopathy 
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Table 11 :COMPARISON OF FFA FINDINGS : 
 
Among the 50 patients with Diabetic Maculopathy, the FFA findings of 
Blocked fluorescence was seen more statistically significant among those 
dyslipidemic patients who had high cholesterol. 
 
 
 
 
90% 85.70% 
80% 77.80% 
70% 
 
60% 
59% 
50% 
 
40% 36% 
30% 
29% 
22% 
20% 
13% 14% 
10% 
Blocked Fluorescence 
Ischemic Retinopathy 
0% 
Cholesterol Triglycerides LDL Normal 
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SUMMARY: 
 
 
 
 
- Age distribution in the group varied from 30-80 years. They were 
categorised into 5 classes with a class interval of 10years each. Majority of 
Diabetics developed Diabetic Maculopathy between the range of 50-60 years of 
age. 
- Among the 50 patiets with Diabetic Maculopathy, 21 were females and 
29 were males. There was a male preponderance in the group. 
- It was found that among the 50 Diabetic patients, 22 patients had Right 
Eye affected with Maculopathy, 24 patients had Left eye affected with 
Maculopathyand 4 patients had both eyes affected with Maculopathy. Majority 
of the patients had Left Eye affected by Diabetic Maculopathy. 
- Among the 50 patients, occupation plot showed that more were coolies 
and housewives. But high serum cholesterol levels were seen in patients with 
sedentary work. 
- Acoording to Body Mass Index(BMI) as per South East Asian 
population standards, the patients in the study were grouped into 3 classes: 
Normal, overweight and. obese. It was found out that most of the patients had a 
normal BMI. 
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- Among the 50 Diabetic patients, fasting lipid profile showed that 19 had 
no abnormality,18 had higher cholesterol levels,9 had high Triglycerides and 4 
had high LDL in blood. 
- Among the 50 Diabetic Maculopathy patients, the Fundus fluorescein 
Angiography showed 2 main patterns: Blocked Fluorescence and Ischemic 
Maculopathy. It was seen that the patients with Blocked fluorescence 
outnumbered those with Ischemic maculopathy. 
- Among the 50 patients, 18 had high cholesterol levels in Lipid profile. On 
FFA, 17 showed Blocked fluorescence and 1 showed Ischemic Maculopathy. 
-Among the 50 patients, 9 had increased levels of Triglycerides in Lipid profile. 
On FFA, 5 showed Blocked fluorescence and 4 showed Ischemic Maculopathy. 
- Among the 50 patients, 4 had high LDL levels in Lipid profile. On FFA, 2 
showed Blocked fluorescence and 2 showed Ischemic Maculopathy. 
-Hence, aamong the 50 patients with Diabetic Maculopathy, the FFA findings 
of Blocked fluorescence was seen more statistically significant among those 
dyslipidemic patients who had high cholesterol wih a p value of 0.042. 
-But the relation between high triglycerides and high LDL to the presence of 
Blocked Fluorescence in FFa was not statistically significant(p value 1.00) 
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DISCUSSION: 
 
The Indian population is considered to have an unusually efficient 
glucose metabolism. With the advent of modernisation and westernisation 
among Indians, the eventual weight gain and sedentary lifestyle, the former 
advantage is lost and incidence of diabetes has increased. Now the disease is 
claiming its toll. With the high prevalence of diabetes, concerns on its morbid 
complications like Diabetic Retinopathy are also increasing. 
 
Hyperglycemia and Dyslipidemia account for the two major 
metabolic disorders seen in patients with diabetes mellitus. The role of diabetic 
dyslipidemia in the development of microvascular complications has not gained 
much attention or depth in world wide literature. 
The present study had a near equal sex distribution with only a slight 
male predominance. Similar male preponderance was also seen in the CURES 
Eye study, UKPDS studyGupta et al and the Andhra Pradesh Eye Disease study 
(APEDS). 
 
The relationship of retinopathy with age was in concordance to that found 
in many other studies which marked an increased prevalence of Diabetic 
Retinopathy with increasing age. Dondana et al CURES Eye Study and APED 
Study also have found significant correlation between the patient age and 
diabetic retinopathy. 
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Epidemiological Study of Diabetic Retinopathy (WESDR) also found that risk 
of retinopathy is directly related to the duration of diabetes. In India, virtually  
all studies have shown an increased prevalence of DR as the duration of 
diabetes increased (Gupta et al, APEDS study, Agarwal et al). 
The CURES Eye Study observed a linear trend between prevalence of DR and 
poor glycemic control. Wisconsin Epidemiological Study of Diabetic 
Retinopathy (WESDR) found that risk of retinopathy is related to the control of 
blood glucose levels. 
 
The present study showed statistically significant correlation  
between diabetic maculopathy (with edema, hard exudates and blocked 
fluorescence) with raised total cholesterol level (p = 0.042). Increased 
cholesterol level was significantly associated with the occurrence of all grades 
of retinopathy among Diabetics. However 
Correlation between Triglycerides and LDL was not statistically 
significant (p = 1.0). Al-Bdour et al and Larsson et al also found significant 
correlation between higher levels of serum total cholesterol and retinopathy. 
Rema et al (CURES eye study) and Haddad et al found that both serum 
triglyceride (p= 0.001) levels and total cholesterol (P= 0.014) were higher in 
patients with diabetic retinopathy as compared to those without diabetic 
retinopathy. In contrast to the present study, Gupta et al demonstrated that 
diabetics with raised LDL levels showed higher prevalence of Diabetic 
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retinopathy (38%) compared to others (28.3%) (p=0.05). Lyons et al and the 
EURODIAB Complications Study found that triglyceride level was related to 
all levels of retinopathy. 
The significant association between hypercholesterolemia and CSME 
goes in accordance with the study by Al-Bdour et al  Wisconsin 
Epidemiological Study of Diabetic Retinopathy (WESDR) and CURES eye 
study. 
The drawbacks of the study are that Optical Coherence 
Tomography(OCT) was not done for all the patients. In such conditions it is 
more common to underestimate than to overestimate fundus changes related to 
diabetic retinopathy. In the present study CSME was diagnosed by Slit lamp 
biomicroscopy with 78D/ 90D lens and Ischemic Maculopathy diagnosed by 
Fundus Fluorescein Angiography. Because of the non-availability, the newer, 
the more sensitive method of assessing retinal thickening such as with optical 
coherence tomography were not used. The study did not evaluate other risk 
factors for the development of retinopathy like anemia. Also, the referral of 
uncontrolled diabetics who could not be included in the study, would have 
allowed the possibility of selection bias to creep into the study. 
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CONCLUSION: 
 
The present study demonstrated statistically significant correlation 
between diabetic retinopathy and hypercholesterolemia (p value 0.042). 
Increased cholesterol level was significantly associated with the occurrence of 
all grades of retinopathy. It also showed that hypercholesterolemia is 
significantly associated with CSME. It has been observed that the appearance of 
hard exudates is consistent with the appearance of dyslipidaemia, which is 
typical for diabetic patients. The aim of this paper was to underline the role of 
elevated serum lipids in the onset of diabetic macular oedema and hard 
exudates. The analysis of the severity of hard exudates and edema in relation to 
lipid fractions in the examined group showed that total cholesterol was 
significantly higher in such patients. Hyperlipidaemia is a risk factor for the 
development of hard exudatesin patients with diabetic maculopathy. The current 
treatment for diabetic retinopathy is laser photocoagulation. With the advent of 
systemic lipid lowering therapy over the last two decades, there may be 
potential for medical therapy also to control dyslipidemic in diabetics thus 
reducing their progression to macular edema. There is some anecdotal evidence 
of the effect of lipid lowering agents in reducing hard exudates. Further studies 
are required to establish the causal relationship between dyslipidemia and 
diabetic retinopathy. If established, these data can lend additional support to 
current treatment guidelines recommending aggressive lowering of elevated 
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lipids among diabetic patients. Efficient lipid control, in addition to its known 
health benefits in preventing cardiovascular disease, can also lessen the ocular 
morbidity and associated health care costs, thereby potentially improving the 
quality of life and vision among people with type 2 diabetes who are more 
prone to develop Diabetic Macular Edema. 
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PROFORMA 
 
NAME: IP/OP NO: 
 
AGE: 
 
 
SEX: FAMILY HISTORY: 
 
INVESTIGATIONS: 
OCULAR EXAMINATION: 
SLIT LAMP EXAMINATION: 
Right eye Left eye 
 
 Conjunctiva  
 Cornea  
 Anterior chamber  
 Iris  
 Pupil  
 Lens  
 Fundus: 
Indirect 90 D 
Media 
Optic disc 
C:D rato 
Vessels 
A:V ratio 
Background 
Macula 
 
Grade of Diabetic Retinopathy 
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FUNDUS FLOURESCEIN ANGIOGRAPHY FINDINGS: 
 
EARLY PHASE OF FFA: 
 
Right eye  Left eye 
Present/absent  Present/absent 
 Leakage in perifoveal area  
 Hyperfluorescence areas  
LATE PHASE OF FFA: 
 
Right eye  Left eye 
Present/absent  Present/absent 
 Leakage in perifoveal area  
 Capillary non perfusion  
 Enlargement of foveal 
avascular zone 
 
 
BIOCHEMICAL TESTS: DATE OF TEST FINDING 
 
FBS   
PPBS   
HBA1C   
LIPID PROFILE   
 
HDL 
  
LDL   
TRIGLYCERIDE   
SERUM CREATININE   
Urine: 
Albumin 
Sugar 
Deposits 
  
90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
 Sl 
No 
 
NAME 
 
AGE 
 
SEX 
 
WORK 
 
EYE 
 
BMI 
LIPID 
PROFILE 
 
FFA 
1 Shekar 62 M Officer LE 23 Cholesterol Blocked Fluo. due to HE 
2 Kalyani 31 F Housewife RE 19 Normal Isch. Maculopathy (↑FAZ) 
3 Shanthi 46 F Housewife LE 24 Cholesterol Blocked Fluo. due to HE 
4 Thangaraj 41 M Coolie RE 26 LDL Blocked Fluo. due to HE 
5 Vijaya 65 F Officer LE 24.5 Triglycerides Blocked Fluo. due to HE 
6 Anbuchelvam 51 M Coolie RE 27 Cholesterol Blocked Fluo. due to HE 
7 Ganeshan 68 M Coolie BE 24 Cholesterol Blocked Fluo. due to HE 
8 Raja 52 M Coolie RE 24.5 LDL Isch. Maculopathy (↑FAZ) 
9 Amritham 71 F Housewife LE 20 Normal Blocked Fluo. due to HE 
10 Palraj 54 M Coolie RE 23 Triglycerides Isch. Maculopathy (↑FAZ) 
11 Veerammal 56 F Housewife LE 24 Cholesterol Blocked Fluo. due to HE 
12 Panju 69 F Coolie LE 22.5 LDL Isch. Maculopathy (↑FAZ) 
13 Kamala 52 F Officer LE 25.5 Cholesterol Blocked Fluo. due to HE 
14 Varatharajan 48 M Officer RE 26 Cholesterol Blocked Fluo. due to HE 
15 Bhuvaneshwari 74 F Housewife LE 19.5 Normal Blocked Fluo. due to HE 
16 Senthil 46 M Officer BE 24 Cholesterol Isch. Maculopathy (↑FAZ) 
17 Kannayya 61 M Coolie RE 21.5 Normal Isch. Maculopathy (↑FAZ) 
18 Shanmugam 52 M Driver RE 24 Triglycerides Isch. Maculopathy (↑FAZ) 
19 Ganga Devi 57 F Housewife RE 23.5 Triglycerides Blocked Fluo. due to HE 
20 Pandiyammal 61 F Coolie LE 20 Normal Blocked Fluo. due to HE 
21 Alagammal 48 F Housewife RE 25 Cholesterol Blocked Fluo. due to HE 
22 Ramjaan Beevi 66 F Housewife LE 19.5 Normal Isch. Maculopathy (↑FAZ) 
23 Krishnan 41 M Officer LE 21 Triglycerides Blocked Fluo. due to HE 
24 Mathiyalagan 42 M Coolie RE 23 Cholesterol Blocked Fluo. due to HE 
25 Poongothai 47 F Officer LE 18.5 Normal Blocked Fluo. due to HE 
 Sl 
No 
NAME AGE SEX WORK EYE BMI 
LIPID 
PROFILE 
FFA 
26 Anna Lakshmi 49 F Housewife BE 24 Cholesterol Blocked Fluo. due to HE 
27 Muthu Krishnan 39 M Tailor RE 22 Normal Blocked Fluo. due to HE 
28 Gunashegaran 55 M Driver LE 19.5 Triglycerides Isch. Maculopathy (↑FAZ) 
29 Subramani 53 M Driver LE 21 LDL Blocked Fluo. due to HE 
30 Aadhi 61 F Housewife RE 21 Normal Isch. Maculopathy (↑FAZ) 
31 Ganga 62 F Housewife RE 25 Cholesterol Blocked Fluo. due to HE 
32 Jayaraj 54 M Officer LE 23 Triglycerides Blocked Fluo. due to HE 
33 Muthu 57 M Painter LE 19.5 Normal Blocked Fluo. due to HE 
34 Dakshinamurthy 48 M Officer RE 18.5 Normal Blocked Fluo. due to HE 
35 Kalyana Sundaram 45 M Officer LE 24 Normal Blocked Fluo. due to HE 
36 Mallika 67 F Housewife RE 19.5 Triglycerides Isch. Maculopathy (↑FAZ) 
37 Chinnaiyya 46 M Coolie LE 21.0 Normal Blocked Fluo. due to HE 
38 Ram Jagan 45 M Coolie BE 25.5 Cholesterol Blocked Fluo. due to HE 
39 Koothan 68 M Coolie RE 19.5 Normal Isch. Maculopathy (↑FAZ) 
40 Ponnusamy 57 M Officer LE 26 Cholesterol Blocked Fluo. due to HE 
41 Saravanan 67 M Coolie RE 21 Normal Blocked Fluo. due to HE 
42 Chellaiyya 56 M Coolie RE 24 Cholesterol Blocked Fluo. due to HE 
43 Kalyani 48 F Tailor LE 20 Normal Blocked Fluo. due to HE 
44 Veeranan 58 M Carpenter RE 21 Cholesterol Blocked Fluo. due to HE 
45 Moideen Beevi 61 F Housewife LE 19.5 Normal Isch. Maculopathy (↑FAZ) 
46 Mani 49 M Coolie LE 18.5 Normal Blocked Fluo. due to HE 
47 Velu 52 M Officer RE 24 Cholesterol Blocked Fluo. due to HE 
48 Mariyammal 62 F Housewife LE 25 Cholesterol Blocked Fluo. due to HE 
49 Pitchai 51 M Coolie RE 21 Normal Isch. Maculopathy (↑FAZ) 
50 Gomathi 64 F Housewife LE 21.5 Triglycerides Blocked Fluo. due to HE 
 LIST OF ABBREVIATIONS: 
 
 
DR- Diabetic Retinopathy 
NPDR- Non Proliferative Diabetic Retinopathy 
PDR- Proliferative Diabetic Retinopathy 
DME- Diabetic Macular Edema 
CSME- Clinically Significant Macular Edema 
FAZ- Foveal Avascular Zone 
FFA- Fundus Fluorescein Angiography 
OCT- Optical Coherence Tomography 
CNP- Capillary Non-Perfusion 
IRMA- Intra Retinal Microvascular Abnormalities 
RE- Right Eye 
LE- Left Eye 
BMI- Body Mass Index 
AGE- Advanced GlycationEndproducts 
LDL- Low Density Lipoproteins 
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